Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255921 | 0.82 | GAA (0.50) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL4483973 | 0.81 | ALOX5 (0.59) | MAOAMAOBALOX5RAB9ANPC1 | |
| SCHEMBL1648301 | 0.81 | BACE1 (0.58) | MAOAMAOBALOX5MAPTTOP1 | |
| SCHEMBL29385685 | 0.78 | ALOX5 (0.54) | MAOAMAOBALOX5RAB9ANPC1 | |
| SCHEMBL26124646 | 0.78 | ALOX5 (0.54) | MAOAMAOBALOX5RAB9ANPC1 | |
| SCHEMBL8327914 | 0.77 | MAOA (0.61) | MAOAMAOBALOX5RAB9ANPC1 | |
| SCHEMBL7066126 | 0.77 | PDGFRB (0.53) | MAOAMAOBALOX5TOP1 | |
| SCHEMBL1646735 | 0.75 | BACE1 (0.49) | MEN1KMT2AERN1CYP3A4 | |
| SCHEMBL3615463 | 0.75 | MAOB (0.58) | MAOAMAOBALOX5RAB9ANPC1 | |
| SCHEMBL20868587 | 0.74 | ALOX5 (0.51) | MAOBALOX5RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099747-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2019-04-04 | — | — | US | disclosed |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| US-9956551-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099747-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | MAOA 535/4885MAOB 753/4885ALOX5 3097/4885 |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | SOD1, MPO, TFRC | MAOA 535/4885MAOB 753/4885ALOX5 3097/4885 |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | MAOA 535/4885MAOB 753/4885ALOX5 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.